PMID- 35432355
OWN - NLM
STAT- MEDLINE
DCOM- 20220419
LR  - 20220708
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Perspectives of JAK Inhibitors for Large Vessel Vasculitis.
PG  - 881705
LID - 10.3389/fimmu.2022.881705 [doi]
LID - 881705
AB  - Vasculitis is an inflammation of the blood vessels caused by autoimmunity and/or 
      autoinflammation, and recent advances in research have led to a better 
      understanding of its pathogenesis. Glucocorticoids and cyclophosphamide have long 
      been the standard of care. However, B-cell depletion therapy with rituximab has 
      become available for treating antineutrophil cytoplasmic antibody-associated 
      vasculitis (AAV). More recently, avacopan, an inhibitor of the complement 5a 
      receptor, was shown to have high efficacy in remission induction against AAV. 
      Thus, treatment options for AAV have been expanded. In contrast, in large vessel 
      vasculitis (LVV), including giant cell arteritis and Takayasu arteritis, 
      tocilizumab, an IL-6 receptor antagonist, was shown to be effective in 
      suppressing relapse and has steroid-sparing effects. However, the relapse rate 
      remains high, and other therapeutic options have long been awaited. In the last 
      decade, Janus kinase (JAK) inhibitors have emerged as therapeutic options for 
      rheumatoid arthritis (RA). Their efficacy has been proven in multiple studies; 
      thus, JAK inhibitors are expected to be promising agents for treating other 
      rheumatic diseases, including LVV. This mini-review briefly introduces the 
      mechanism of action of JAK inhibitors and their efficacy in patients with RA. 
      Then, the pathophysiology of LVV is updated, and a rationale for treating LVV 
      with JAK inhibitors is provided with a brief introduction of our preliminary 
      results using a mouse model. Finally, we discuss the newly raised safety concerns 
      regarding JAK inhibitors and future perspectives for treating LVV.
CI  - Copyright (c) 2022 Watanabe and Hashimoto.
FAU - Watanabe, Ryu
AU  - Watanabe R
AD  - Department of Clinical Immunology, Osaka City University Graduate School of 
      Medicine, Osaka, Japan.
FAU - Hashimoto, Motomu
AU  - Hashimoto M
AD  - Department of Clinical Immunology, Osaka City University Graduate School of 
      Medicine, Osaka, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220330
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Janus Kinase Inhibitors)
SB  - IM
MH  - *Arteritis
MH  - *Giant Cell Arteritis/drug therapy
MH  - Humans
MH  - *Janus Kinase Inhibitors/pharmacology/therapeutic use
MH  - Recurrence
MH  - *Takayasu Arteritis/drug therapy
PMC - PMC9005632
OTO - NOTNLM
OT  - JAK inhibitors
OT  - Janus kinase (JAK)
OT  - Takayasu arteritis
OT  - giant cell arteritis
OT  - large vessel vasculitis
COIS- RW receives speaker's fee from Eli Lilly. MH receives research grants from 
      AbbVie, Asahi-Kasei, Brystol-Meyers, Eisai, Eli Lilly, Novartis Pharma.
EDAT- 2022/04/19 06:00
MHDA- 2022/04/20 06:00
PMCR- 2022/01/01
CRDT- 2022/04/18 06:34
PHST- 2022/02/22 00:00 [received]
PHST- 2022/03/09 00:00 [accepted]
PHST- 2022/04/18 06:34 [entrez]
PHST- 2022/04/19 06:00 [pubmed]
PHST- 2022/04/20 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.881705 [doi]
PST - epublish
SO  - Front Immunol. 2022 Mar 30;13:881705. doi: 10.3389/fimmu.2022.881705. eCollection 
      2022.